{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:32:29Z","timestamp":1794562349370,"version":"4.9.1"},"reference-count":105,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,17]],"date-time":"2027-09-17T00:00:00Z","timestamp":1821139200000},"content-version":"am","delay-in-days":351,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100030820","name":"Drug Discovery Center, College of Pharmacy, Health Science Center, University of Tennessee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030820","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.dmd.2026.100394","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:51:38Z","timestamp":1787755898000},"page":"100394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of CYP3A4 in the metabolism of tyrosine kinase inhibitors in non\u2013small cell lung cancer therapy"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9814-8411","authenticated-orcid":false,"given":"Sara","family":"Sultana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-5449","authenticated-orcid":false,"given":"Mir Shahriar","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9522-4474","authenticated-orcid":false,"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.dmd.2026.100394_bib1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032899","article-title":"Non-small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment","volume":"102","author":"Alduais","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.dmd.2026.100394_bib2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.hoc.2012.02.001","article-title":"Tyrosine kinase inhibitors in lung cancer","volume":"26","author":"Thomas","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-9966-33-15","article-title":"Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective","volume":"33","author":"Eckstein","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.dmd.2026.100394_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108660","article-title":"Therapeutic dominance of tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC)","volume":"163","author":"Shivika","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.dmd.2026.100394_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108107","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update","volume":"224","author":"Roskoski","year":"2026","journal-title":"Pharmacol Res"},{"issue":"9","key":"10.1016\/j.dmd.2026.100394_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/11593320-000000000-00000","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles","volume":"50","author":"Di Gion","year":"2011","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100394_bib9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7150\/ijms.1.101","article-title":"Tyrosine kinase \u2013 role and significance in cancer","volume":"1","author":"Paul","year":"2004","journal-title":"Int J Med Sci"},{"issue":"S10","key":"10.1016\/j.dmd.2026.100394_bib10","doi-asserted-by":"crossref","first-page":"S1592","DOI":"10.21037\/tcr.2017.09.10","article-title":"Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity","volume":"6","author":"Mikus","year":"2017","journal-title":"Trans Cancer Res"},{"issue":"2","key":"10.1016\/j.dmd.2026.100394_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/bcp.12496","article-title":"Metabolism-related pharmacokinetic drug\u2212drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations","volume":"79","author":"Teo","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100394_bib12","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.3390\/ijms19082367","article-title":"Role of cytochrome P450 enzymes in the metabolic activation of tyrosine kinase inhibitors","volume":"19","author":"Jackson","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.dmd.2026.100394_bib13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2125.1995.tb05796.x","article-title":"The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions","volume":"40","author":"Kivisto","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmd.2026.100394_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/or.2025.1612249","article-title":"Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide","volume":"19","author":"Santamaria","year":"2025","journal-title":"Oncol Rev"},{"issue":"12","key":"10.1016\/j.dmd.2026.100394_bib15","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1158\/1078-0432.CCR-07-0088","article-title":"Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes","volume":"13","author":"Li","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100394_bib16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/bcp.15544","article-title":"Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours","volume":"89","author":"Chen","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100394_bib17","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1021\/acs.jafc.2c00237","article-title":"Dietary inhibitors of CYP3A4 are revealed using virtual screening by using a new deep-learning classifier","volume":"70","author":"Guttman","year":"2022","journal-title":"J Agric Food Chem"},{"issue":"5","key":"10.1016\/j.dmd.2026.100394_bib18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/JTO.0b013e3181d32287","article-title":"Pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small cell lung cancer and chronic renal failure who are undergoing hemodialysis","volume":"5","author":"Togashi","year":"2010","journal-title":"J Thoracic Oncol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100394_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00280-010-1332-y","article-title":"Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN)","volume":"67","author":"Kraut","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dmd.2026.100394_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2021.122554","article-title":"Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification","volume":"1166","author":"Rood","year":"2021","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"3","key":"10.1016\/j.dmd.2026.100394_bib21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FTD.0000000000001157","article-title":"A validated assay to quantify osimertinib and its metabolites, AZ5104 and AZ7550, from microsampled dried blood spots and plasma","volume":"46","author":"Venkatesh","year":"2024","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.dmd.2026.100394_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/bdd.2347","article-title":"Metabolism and pharmacokinetic study of deuterated osimertinib","volume":"44","author":"Zhan","year":"2023","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.dmd.2026.100394_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104297","article-title":"e al. Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein)","volume":"146","author":"van Hoppe","year":"2019","journal-title":"Pharmacol Res"},{"issue":"8","key":"10.1016\/j.dmd.2026.100394_bib24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.115.069203","article-title":"Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor","volume":"44","author":"Dickinson","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100394_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/psp4.12289","article-title":"Development, verification, and prediction of osimertinib drug\u2013drug interactions using PBPK modeling approach to inform drug label","volume":"7","author":"Pilla Reddy","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100394_bib26","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1158\/1078-0432.CCR-17-3555","article-title":"Identification of novel pathways of osimertinib disposition and potential implications for the outcome of lung cancer therapy","volume":"24","author":"MacLeod","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.dmd.2026.100394_bib27","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/2159-8290.CD-21-1615","article-title":"Sunvozertinib, a selective EGFR inhibitor for previously treated non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"12","author":"Wang","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00228-007-0396-z","article-title":"The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition","volume":"64","author":"Rakhit","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100394_bib30","doi-asserted-by":"crossref","first-page":"e496","DOI":"10.1016\/j.cllc.2025.05.012","article-title":"Osimertinib dose optimization guided by therapeutic drug monitoring in patients with EGFR-mutated advanced non-small cell lung cancer: a case series","volume":"26","author":"Kruithof","year":"2025","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"10.1016\/j.dmd.2026.100394_bib31","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00228-015-1945-5","article-title":"The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects","volume":"71","author":"Xu","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100394_bib32","first-page":"267","article-title":"Crizotinib: a breakthrough for targeted therapies in lung cancer","volume":"3","author":"Kwon","year":"2012","journal-title":"J Adv Pract Oncol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100394_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2017.e00354","article-title":"Metabolites of alectinib in human: their identification and pharmacological activity","volume":"3","author":"Sato-Nakai","year":"2017","journal-title":"Heliyon"},{"key":"10.1016\/j.dmd.2026.100394_bib34","author":"Keegan"},{"issue":"3","key":"10.1016\/j.dmd.2026.100394_bib35","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/cpdd.298","article-title":"Clinical drug-drug interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib","volume":"6","author":"Morcos","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"12","key":"10.1016\/j.dmd.2026.100394_bib36","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1158\/1078-0432.CCR-17-2398","article-title":"Ensartinib (X-396) in ALK-positive non-small cell lung cancer: results from a first-in-human phase I\/II, multicenter study","volume":"24","author":"Horn","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.dmd.2026.100394_bib38","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1124\/dmd.123.001373","article-title":"Prediction of drug-drug interactions with ensartinib as a time-dependent CYP3A inhibitor using physiologically based pharmacokinetic model","volume":"51","author":"Wang","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100394_bib39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00280-020-04180-3","article-title":"Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug-drug interaction study in patients with ALK + advanced tumors","volume":"87","author":"Hurtado","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.dmd.2026.100394_bib40","author":"Blumenthal"},{"key":"10.1016\/j.dmd.2026.100394_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112974","article-title":"Entrectinib, a new multi-target inhibitor for cancer therapy","volume":"150","author":"Jiang","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.dmd.2026.100394_bib43","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/cpt.3386","article-title":"PBPK modeling of entrectinib and its active metabolite to derive dose adjustments in pediatric populations co-administered with CYP3A4 inhibitors","volume":"116","author":"Umehara","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100394_bib44","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10637-020-01047-5","article-title":"Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors","volume":"39","author":"Meneses-Lorente","year":"2021","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10637-021-01156-9","article-title":"In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK)","volume":"40","author":"Meneses-Lorente","year":"2022","journal-title":"Invest New Drugs"},{"issue":"4","key":"10.1016\/j.dmd.2026.100394_bib47","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s10147-008-0871-2","article-title":"Effect of gefitinib on warfarin antithrombotic activity","volume":"14","author":"Arai","year":"2009","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100394_bib48","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2125.2009.03438.x","article-title":"Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers","volume":"68","author":"Chhun","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100394_bib49","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2165\/00003088-200544100-00005","article-title":"Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol","volume":"44","author":"Swaisland","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"22","key":"10.1016\/j.dmd.2026.100394_bib50","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.jchromb.2011.05.056","article-title":"Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry","volume":"879","author":"Wang","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100394_bib51","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/1872312808666140317154110","article-title":"Metabolite characterization of anti-cancer agent gefitinib in human hepatocytes","volume":"7","author":"Surve","year":"2014","journal-title":"Drug Metab Lett"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1476-4598-10-143","article-title":"Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines","volume":"10","author":"Alfieri","year":"2011","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.dmd.2026.100394_bib54","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/psp4.13106","article-title":"Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach","volume":"13","author":"Hanley","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100394_bib55","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s40262-023-01284-w","article-title":"Clinical pharmacology of brigatinib: a next-generation anaplastic lymphoma kinase inhibitor","volume":"62","author":"Gupta","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmd.2026.100394_bib56","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/jcph.2198","article-title":"A phase 1 drug-drug interaction study between brigatinib and the CYP3A substrate midazolam in patients with ALK-positive or ROS1-positive solid tumors","volume":"63","author":"Hanley","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100394_bib58","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1007\/s40262-021-01026-w","article-title":"The effect of modafinil on the safety and pharmacokinetics of lorlatinib: a phase I study in healthy participants","volume":"60","author":"Li","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.dmd.2026.100394_bib59","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40262-021-01015-z","article-title":"Pharmacokinetics of lorlatinib after single and multiple dosing in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer: results from a global phase I\/II study","volume":"60","author":"Chen","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100394_bib61","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/10781552221147500","article-title":"An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)","volume":"29","author":"Nguyen","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.dmd.2026.100394_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2025.117393","article-title":"Potent and highly selective inhibition of selpercatinib towards UDP-glucuronosyltransferase 1A4 (UGT1A4) isoform","volume":"500","author":"Liu","year":"2025","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100394_bib63","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/jcph.2153","article-title":"Evaluation of the pharmacokinetic drug interaction of capmatinib with itraconazole and rifampicin and potential impact on renal transporters in healthy subjects","volume":"63","author":"Cui","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.dmd.2026.100394_bib64","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1124\/dmd.119.090324","article-title":"Absorption, distribution, metabolism, and excretion of capmatinib (INC280) in healthy male volunteers and in vitro aldehyde oxidase phenotyping of the major metabolite","volume":"48","author":"Glaenzel","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib66","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/2159-8290.CD-25-0605","article-title":"Sevabertinib, a reversible HER2 inhibitor with activity in lung cancer","volume":"16","author":"Siegel","year":"2026","journal-title":"Cancer Discov"},{"issue":"18","key":"10.1016\/j.dmd.2026.100394_bib67","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","article-title":"Sevabertinib in advanced HER2-mutant non-small-cell lung cancer","volume":"393","author":"Le","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dmd.2026.100394_bib68","author":"Stephenson"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib70","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/med.2610030105","article-title":"The metabolism of tertiary amines","volume":"3","author":"Rose","year":"1983","journal-title":"Med Res Rev"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib71","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/psp4.13255","article-title":"Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates","volume":"14","author":"Izat","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100394_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/dta.3008","article-title":"High-resolution mass spectrometry-based approach for the identification and profiling of the metabolites of taletrectinib formed in liver microsomes","volume":"13","author":"Ye","year":"2021","journal-title":"Drug Test Anal"},{"issue":"7","key":"10.1016\/j.dmd.2026.100394_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70273","article-title":"Sensitivity of tepotinib to inhibitors or inducers of CYP3A4 and P-Gp: drug interaction studies and physiologically-based pharmacokinetic analysis","volume":"18","author":"Strotmann","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.dmd.2026.100394_bib75","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s10637-023-01378-z","article-title":"Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substrates","volume":"41","author":"Yalkinoglu","year":"2023","journal-title":"Invest New Drugs"},{"issue":"5","key":"10.1016\/j.dmd.2026.100394_bib76","article-title":"Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates","volume":"30","author":"Yalkinoglu","year":"2019","journal-title":"Annals of Oncology"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib79","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1186\/s12885-023-10939-7","article-title":"Impact of polypharmacy and comorbidity on survival and systemic parenteral treatment administration in a cohort of hospitalized lung-cancer patients","volume":"23","author":"Pluchart","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.dmd.2026.100394_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1016976","article-title":"Lung cancer, comorbidities, and medication: the infernal trio","volume":"14","author":"Pluchart","year":"2024","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.dmd.2026.100394_bib81","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/ph18070959","article-title":"Beyond the basics: exploring pharmacokinetic interactions and safety in tyrosine-kinase inhibitor oral therapy for solid tumors","volume":"18","author":"Bud\u0103u","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.dmd.2026.100394_bib82","article-title":"Safety and efficacy of osimertinib 160 mg daily given concurrently with a strong CYP3A4 inducer","volume":"55","author":"Aglan","year":"2025","journal-title":"Respir Med Case Rep"},{"issue":"5","key":"10.1016\/j.dmd.2026.100394_bib83","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1124\/dmd.121.000765","article-title":"Estimation of fraction metabolized by cytochrome P450 enzymes using long-term cocultured human hepatocytes","volume":"50","author":"Klammers","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100394_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2025.100818","article-title":"Understanding pharmacokinetic-drug interactions with drugs approved by the US Food and Drug Administration in 2024 to better manage the risk of drug interactions with concomitant medications: a review of clinical data from new drug applications","volume":"104","author":"Yu","year":"2026","journal-title":"Curr Ther Res Clin Exp"},{"issue":"6","key":"10.1016\/j.dmd.2026.100394_bib85","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/bcp.13534","article-title":"The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib","volume":"84","author":"Vishwanathan","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100394_bib86","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/bcp.13953","article-title":"Erlotinib treatment induces cytochrome P450 3A activity in non-small cell lung cancer patients","volume":"85","author":"Svedberg","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100394_bib87","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40262-023-01309-4","article-title":"Evaluation of the effect of lorlatinib on CYP2B6, CYP2C9, UGT, and P-glycoprotein substrates in patients with advanced non-small cell lung cancer","volume":"63","author":"Chen","year":"2024","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmd.2026.100394_bib88","first-page":"189","article-title":"Drug-drug interactions, safety, and pharmacokinetics of EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer","volume":"9","author":"Kucharczuk","year":"2018","journal-title":"J Adv Pract Oncol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100880","article-title":"Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure","volume":"8","author":"Raoul","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib90","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1038\/s41598-022-10938-x","article-title":"Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib","volume":"12","author":"Lee","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.dmd.2026.100394_bib91","doi-asserted-by":"crossref","first-page":"8539","DOI":"10.2147\/CMAR.S222278","article-title":"Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment \u2013 a nationwide population-based study","volume":"11","author":"Fang","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.dmd.2026.100394_bib92","article-title":"Deleterious association between proton pump inhibitor and protein kinase inhibitor exposure and survival for patients with lung cancer: a nationwide cohort study","volume":"39","author":"Bordet","year":"2024","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.dmd.2026.100394_bib93","article-title":"The influence of CYP3A4 genetic polymorphism and proton pump Inhibitors on osimertinib metabolism","volume":"13","author":"Gao","year":"2022","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100394_bib94","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1124\/dmd.122.001131","article-title":"Activation\/inactivation of anticancer drugs by CYP3A4: influencing factors for personalized cancer therapy","volume":"51","author":"Wang","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100394_bib95","article-title":"CYP3A4 and CYP3A5: the crucial roles in clinical drug metabolism and the significant implications of genetic polymorphisms","volume":"12","author":"Zhang","year":"2024","journal-title":"PeerJ"},{"issue":"2","key":"10.1016\/j.dmd.2026.100394_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2024.100025","article-title":"Impact of sex and pregnancy on hepatic CYP3A4 expression and activity in a humanized mouse model","volume":"53","author":"Fashe","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100394_bib97","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1002\/jcph.1286","article-title":"Effect of hepatic impairment on the pharmacokinetics of alectinib","volume":"58","author":"Morcos","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmd.2026.100394_bib98","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","article-title":"Cytochrome P450 3A: ontogeny and drug disposition","volume":"37","author":"de Wildt","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.dmd.2026.100394_bib99","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s00044-024-03360-7","article-title":"CYP3A4 drug metabolism considerations in pediatric pharmacotherapy","volume":"33","author":"Vander Schaaf","year":"2024","journal-title":"Med Chem Res"},{"issue":"11","key":"10.1016\/j.dmd.2026.100394_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103965","article-title":"Safety of solid oncology drugs in older patients: a narrative review","volume":"9","author":"Rousseau","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.dmd.2026.100394_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1652750","article-title":"Risk of interstitial lung disease in non-small cell lung cancer treated with EGFR-TKI: a real-world pharmacovigilance study","volume":"16","author":"Miao","year":"2025","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100394_bib102","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s00210-025-04721-8","article-title":"Biological sex differences in pharmacokinetics and adverse drug reactions","volume":"399","author":"Aljohmani","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98689-z","article-title":"Effect of CYP3A4 metabolism on sex differences in the pharmacokinetics and pharmacodynamics of zolpidem","volume":"11","author":"Yoon","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.dmd.2026.100394_bib104","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bcpt.13246","article-title":"Functional characterization of 27 CYP3A4 protein variants to metabolize regorafenib in vitro","volume":"125","author":"Li","year":"2019","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.dmd.2026.100394_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2024.117016","article-title":"The impact of CYP3A4 genetic polymorphism on crizotinib metabolism and drug-drug interactions","volume":"489","author":"Wang","year":"2024","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100394_bib106","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40262-018-0719-5","article-title":"Impact of CYP3A4\u221722 on pazopanib pharmacokinetics in cancer patients","volume":"58","author":"Bins","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib107","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/clpt.2014.47","article-title":"Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662","volume":"96","author":"Diekstra","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dmd.2026.100394_bib108","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s40262-023-01260-4","article-title":"CYP3A4\u221722 genotype-guided dosing of kinase inhibitors in cancer patients","volume":"62","author":"van Eerden","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.dmd.2026.100394_bib109","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/dmd.121.000356","volume":"49","author":"Eng","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100394_bib110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/0113892002312369240703102215","article-title":"Role of cytochrome P450 3A4 in cancer drug resistance: challenges and opportunities","volume":"25","author":"Pandey","year":"2024","journal-title":"Curr Drug Metab"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib111","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41392-024-02021-w","article-title":"Liquid biopsy in cancer current: status, challenges and future prospects","volume":"9","author":"Ma","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"10.1016\/j.dmd.2026.100394_bib112","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3390\/genes12030349","article-title":"Liquid biopsies: applications for cancer diagnosis and monitoring","volume":"12","author":"Martins","year":"2021","journal-title":"Genes (Basel)"},{"issue":"10","key":"10.1016\/j.dmd.2026.100394_bib113","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/psp4.12343","article-title":"PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin","volume":"7","author":"Hanke","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100394_bib114","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/cpt.622","article-title":"Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: frequent utilization in the field of oncology","volume":"101","author":"Yoshida","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dmd.2026.100394_bib115","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/bcp.16070","article-title":"Therapeutic drug monitoring of osimertinib in EGFR mutant non-small cell lung cancer by dried blood spot and plasma collection: a pilot study","volume":"90","author":"Narayanan","year":"2024","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100394_bib116","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s12672-025-03376-4","article-title":"Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics","volume":"16","author":"Li","year":"2025","journal-title":"Discov Oncol"},{"issue":"35","key":"10.1016\/j.dmd.2026.100394_bib117","doi-asserted-by":"crossref","first-page":"13673","DOI":"10.1021\/acs.inorgchem.2c02587","article-title":"Ir(III)-based agents for monitoring the cytochrome P450 3A4 active site occupancy","volume":"61","author":"Denison","year":"2022","journal-title":"Inorg Chem"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600663X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009095562600663X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T09:19:51Z","timestamp":1794561591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009095562600663X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":105,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S009095562600663X"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100394","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of CYP3A4 in the metabolism of tyrosine kinase inhibitors in non\u2013small cell lung cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100394"}}